2026 Interim report
Filed with HKEX · Stock code 1093 · · 71 pages · English
2 Corporate Information 3 Financial Highlights 30 Report on Review of Condensed Consolidated Financial Statements 31 Condensed Consolidated Income Statement 32 Condensed Consolidated Statement of Comprehensive Income 33 Condensed Consolidated Statement of Financial Position 35 Condensed Consolidated Statement of Changes In Equity 36 Condensed Consolidated Statement of Cash Flows 38 Notes to the Co
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Voluntary announcement - phase II clinical trial of SYH2069 injection for the treatment of type 2 diabetes mellitus in adult patients officially initiated at the first centre in China
- Voluntary announcement - SYS6010 granted Breakthrough Therapy Designation by NMPA in China for the treatment of patients with actionable genomic alteration-negative non-squamous non-small cell lung cancer
- Voluntary announcement - phase i/ii clinical trial data of SYS6010 in combination with enlonstobart for the treatment of systemic treatment-naive, actionable genomic alteration-negative advanced nsclc orally presented at the 2026 world conference on lung cancer (wclc)
- Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
- Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
Later from CSPC Pharmaceutical
- Letter to new registered shareholders and reply form
- Notification letter to non-registered holder and request form
- Notification letter to shareholder and change request form
- Voluntary announcement - phase III clinical trial of docetaxel for injection (albumin-bound) (HB1801) for the treatment of advanced breast cancer officially initiated in china
- Voluntary announcement - phase III clinical trial of becotatug (JMT101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic NSCLC harbouring EGFR exon 20 insertion mutations achieves positive topline results
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical